trilostane has been researched along with Carcinoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auchus, RJ; Evaul, K; Li, R; Papari-Zareei, M; Sharifi, N | 1 |
| Carlström, K; Döberl, A; Pousette, A; Rannevik, G; Wilking, N | 1 |
| Komanicky, P; Melby, JC; Spark, RF | 1 |
| Barley, V; Blackledge, G; Hutcheon, A; Kaye, S; Keen, C; Rowland, C; Smith, D; Tyrrell, C; Webster, DJ; Williams, CJ | 1 |
4 other study(ies) available for trilostane and Carcinoma
| Article | Year |
|---|---|
3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Nucleus; Dehydroepiandrosterone; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Male; Models, Biological; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Treatment Failure | 2010 |
Inhibition of steroid sulfatase activity by danazol.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma; Culture Techniques; Danazol; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estrogen Antagonists; Estrone; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Pregnadienes; Tamoxifen | 1984 |
Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Adult; Blood Pressure; Carcinoma; Cushing Syndrome; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Female; Humans; Hydrocortisone; Kinetics; Male; Middle Aged; Mineralocorticoids; Potassium; Renin | 1978 |
Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer.
Topics: Breast Neoplasms; Carcinoma; Dexamethasone; Dihydrotestosterone; Female; Humans; Menopause; Multi-Institutional Systems | 1987 |